A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody

A Phase II, Single-Center, Randomized, Blinded, Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody Injection in Healthy Subjects

A Phase II, Single-Center, Randomized, Blinded, Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody Injection in Healthy Subjects

Study Overview

• Status: Not yet recruiting
• Conditions: Rabies (Healthy Volunteers)
• Intervention / Treatment: Drug: Recombinant Human Rabies Virus Monoclonal Antibody Injection; Drug: Human Rabies Immunoglobulin (HRIG); Biological: Rabies Vaccine; Drug: Placebo

Detailed Description

Primary Objective of the study:

（1）To evaluate the safety, tolerability, and Rabies Virus Neutralizing Activity (RVNA) of different doses of a recombinant human anti-rabies virus monoclonal antibody injection (referred to as the anti-rabies mAb), administered alone or in combination with a human rabies vaccine, compared to human rabies immune globulin, in healthy adult participants aged 18-60.

Secondary Objective of the study:

1. To evaluate the pharmacokinetics (PK) of the anti-rabies mAb administered alone or in combination with a human rabies vaccine in healthy adult participants aged 18-60.
2. To evaluate the incidence of anti-drug antibodies for the anti-rabies mAb compared to human rabies immune globulin, administered alone or in combination with a human rabies vaccine, in healthy adult participants aged 18-60.
3. To provide a basis for dose selection for Phase III clinical studies.

• Study Type: Interventional
• Enrollment (Estimated): 200
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Jijun Chen; Phone Number: +86 13919275320; Email: chenjijun@sinopharm.com

Study Locations

• China
  • Gansu
    • Lanzhou, Gansu, China, 730000
      • Lanzhou Institute of Biological Products Co., Ltd.
      • Contact: Jijun Chen; Phone Number: +86 13919275320; Email: chenjijun@sinopharm.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Healthy individuals aged 18-60 years (inclusive), regardless of gender, capable of providing valid legal identification.
2. Participants voluntarily agree to participate in the study and sign an informed consent form.
3. Female participants must have no plans for pregnancy or egg donation from 14 days prior to dosing until 6 months after dosing and must voluntarily adopt effective physical contraceptive measures. Male participants must have no plans for pregnancy or sperm donation within 6 months after dosing and must voluntarily adopt effective physical contraceptive measures.
4. Female participants must weigh ≥45.0 kg and ≤80.0 kg, and male participants must weigh ≥50.0 kg and ≤80.0 kg. Body mass index (BMI) must be between 18.0 and 26.0 kg/m² (inclusive) (BMI = weight in kg / height in m²).
5. Vital signs (reference ranges: systolic blood pressure 90-140 mmHg, diastolic blood pressure 60-90 mmHg, pulse rate 50-100 beats per minute, all inclusive; body temperature assessed by the investigator according to the research center's standards), physical examination, and clinical laboratory and auxiliary tests during the screening period must be normal or judged by the investigator to have no clinical significance if abnormal.

Exclusion Criteria:

1. Known allergy to the investigational product (including excipients or similar drugs), or individuals with a history of severe allergic diseases or considered allergic constitution (e.g., allergies to two or more drugs, foods, or pollen) as judged by the investigator to potentially compromise participant safety.
2. Clear history of allergy to essential substances that may be encountered during the trial (e.g., skin disinfectants).
3. History of clinically severe diseases within the 6 months (180 days) prior to screening that remain unresolved, or current acute or chronic illnesses that may significantly affect the metabolism or safety evaluation of the investigational product.
4. History of autoimmune diseases or chronic hepatitis.
5. History of seizures, epilepsy, psychiatric or neurological disorders, or family history of seizures or epilepsy.
6. Major surgery within the 3 months (90 days) prior to screening, or surgery that may significantly affect the metabolism or safety evaluation of the investigational product.
7. Previous vaccination with human rabies vaccine, or suspected history of rabies exposure (defined as bites, scratches, licks on mucous membranes or broken skin by rabid, suspected rabid, or undetermined rabies status animals, or direct contact of open wounds or mucous membranes with saliva or tissues potentially containing rabies virus), as determined by inquiry.
8. Positive screening for anti-rabies virus antibodies during the screening period.
9. Vaccination with any vaccine other than the rabies vaccine within the 1 month (30 days) prior to screening.
10. Use of other antibody-based drugs or immunoglobulins within the 3 months (90 days) prior to screening.
11. Use of passive immunizing agents, immunosuppressants, or corticosteroids within the 3 months (90 days) prior to screening.
12. Use of medications that may affect the metabolism or safety evaluation of the investigational product within the 14 days prior to screening or ongoing use of such medications.
13. Participation in any clinical trial involving the use of investigational drugs or devices within the 3 months (90 days) prior to screening, or planned participation in other clinical trials during this study.
14. Regular alcohol consumption within the 3 months (90 days) prior to screening, averaging more than 2 alcohol units per day (1 unit = 17.7 mL ethanol, equivalent to 357 mL of 5% beer, 43 mL of 40% spirits, or 147 mL of 12% wine), or inability to abstain from alcohol during the trial period.
15. Smoking habit within the 3 months (90 days) prior to screening (more than 5 cigarettes or equivalent tobacco per day), or inability to abstain from smoking during the trial period.
16. Blood loss/donation exceeding 300 mL (excluding physiological blood loss in females) within the 3 months (90 days) prior to screening, receipt of blood transfusions or blood products, or plans to donate blood within 1 month (30 days) after the trial.
17. Inability to avoid strenuous exercise within 14 days after dosing.
18. History of drug abuse.
19. Pregnant or breastfeeding women.
20. History of needle or blood phobia, poor vascular condition, or intolerance to venipuncture.
21. Participants who may be unable to cooperate in completing the study for other reasons or are deemed unsuitable for inclusion by the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

7

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group 1：40 IU/kg monoclonal antibody - Monotherapy Study; 60 trial participants were enrolled and randomly assigned at a 1:1:1 ratio to the 40 IU/kg monoclonal antibody group (20 participants), the HRIG control group (20 participants), and the 80 IU/kg monoclonal antibody group (20 participants).	Drug: Recombinant Human Rabies Virus Monoclonal Antibody Injection; On Day 0, administer via intramuscular injection into the lateral thigh. It is strictly prohibited to use the same syringe as the rabies vaccine or to co-administer at the same injection site.
Experimental: Group 2: 80 IU/kg monoclonal antibody - Monotherapy Study; 60 trial participants were enrolled and randomly assigned at a 1:1:1 ratio to the 40 IU/kg monoclonal antibody group (20 participants), the HRIG control group (20 participants), and the 80 IU/kg monoclonal antibody group (20 participants).	Drug: Recombinant Human Rabies Virus Monoclonal Antibody Injection; On Day 0, administer via intramuscular injection into the lateral thigh. It is strictly prohibited to use the same syringe as the rabies vaccine or to co-administer at the same injection site.
Experimental: Group 3: HRIG (20 IU/kg) group - Monotherapy Study; 60 trial participants were enrolled and randomly assigned at a 1:1:1 ratio to the 40 IU/kg monoclonal antibody group (20 participants), the HRIG control group (20 participants), and the 80 IU/kg monoclonal antibody group (20 participants).	Drug: Human Rabies Immunoglobulin (HRIG); On Day 0, administration shall be performed via intramuscular injection into the lateral aspect of the thigh. It is strictly prohibited to use the same syringe as the rabies vaccine or to administer both agents at the same injection site.
Experimental: Group 4：40 IU/kg monoclonal antibody plus vaccine - Combined Administration Study; A total of 140 trial participants were enrolled and randomly assigned in a 2:2:2:1 ratio to the following groups: 40 IU/kg monoclonal antibody plus vaccine group (40 participants) HRIG plus vaccine group (40 participants) 80 IU/kg monoclonal antibody plus vaccine group (40 participants) Placebo plus vaccine group (20 participants).	Drug: Recombinant Human Rabies Virus Monoclonal Antibody Injection; On Day 0, administer via intramuscular injection into the lateral thigh. It is strictly prohibited to use the same syringe as the rabies vaccine or to co-administer at the same injection site.; Biological: Rabies Vaccine; On Days 0, 3, 7, 14, and 28, administer via intramuscular injection into the deltoid muscle of the upper arm. Injection into the gluteal region is prohibited. The injection on Day 0 should be administered as soon as possible after the administration of the investigational product.
Experimental: Group 5：80 IU/kg monoclonal antibody plus vaccine - Combined Administration Study; A total of 140 trial participants were enrolled and randomly assigned in a 2:2:2:1 ratio to the following groups: 40 IU/kg monoclonal antibody plus vaccine group (40 participants) HRIG plus vaccine group (40 participants) 80 IU/kg monoclonal antibody plus vaccine group (40 participants) Placebo plus vaccine group (20 participants).	Drug: Recombinant Human Rabies Virus Monoclonal Antibody Injection; On Day 0, administer via intramuscular injection into the lateral thigh. It is strictly prohibited to use the same syringe as the rabies vaccine or to co-administer at the same injection site.; Biological: Rabies Vaccine; On Days 0, 3, 7, 14, and 28, administer via intramuscular injection into the deltoid muscle of the upper arm. Injection into the gluteal region is prohibited. The injection on Day 0 should be administered as soon as possible after the administration of the investigational product.
Experimental: Group 6: HRIG (20 IU/kg) plus vaccine - Combined Administration Study; A total of 140 trial participants were enrolled and randomly assigned in a 2:2:2:1 ratio to the following groups: 40 IU/kg monoclonal antibody plus vaccine group (40 participants) HRIG plus vaccine group (40 participants) 80 IU/kg monoclonal antibody plus vaccine group (40 participants) Placebo plus vaccine group (20 participants).	Drug: Human Rabies Immunoglobulin (HRIG); On Day 0, administration shall be performed via intramuscular injection into the lateral aspect of the thigh. It is strictly prohibited to use the same syringe as the rabies vaccine or to administer both agents at the same injection site.; Biological: Rabies Vaccine; On Days 0, 3, 7, 14, and 28, administer via intramuscular injection into the deltoid muscle of the upper arm. Injection into the gluteal region is prohibited. The injection on Day 0 should be administered as soon as possible after the administration of the investigational product.
Experimental: Group 7: placebo plus vaccine - Combined Administration Study; A total of 140 trial participants were enrolled and randomly assigned in a 2:2:2:1 ratio to the following groups: 40 IU/kg monoclonal antibody plus vaccine group (40 participants) HRIG plus vaccine group (40 participants) 80 IU/kg monoclonal antibody plus vaccine group (40 participants) Placebo plus vaccine group (20 participants).	Biological: Rabies Vaccine; On Days 0, 3, 7, 14, and 28, administer via intramuscular injection into the deltoid muscle of the upper arm. Injection into the gluteal region is prohibited. The injection on Day 0 should be administered as soon as possible after the administration of the investigational product.; Drug: Placebo; On Day 0, administration shall be performed via intramuscular injection into the lateral aspect of the thigh. It is strictly prohibited to use the same syringe as the rabies vaccine or to administer both agents at the same injection site.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Occurrence of any local and systemic adverse events (AEs) within at least 30 minutes after administration of the investigational product/vaccine.	Local and systemic adverse events (AEs)	At least 30 minutes after administration
Occurrence of any local AEs, systemic AEs, and serious adverse events (SAEs) from the administration of the investigational product on Day 0 until the last visit.	Local AEs, systemic AEs, and serious adverse events (SAEs)	0-105 days
Vital signs changes from baseline at different observation time points following the administration of the investigational product/vaccine.	Tympanic temperature（℃）	0-105 Days
Vital signs changes from baseline at different observation time points following the administration of the investigational product/vaccine.	Systolic Pressure and Diastolic Pressure (Sitting Position) （mmHg）	0-105 Days
Vital signs changes from baseline at different observation time points following the administration of the investigational product/vaccine.	Pulse（bpm）	0-105 Days
Changes in 12-lead electrocardiogram findings from baseline at different observation time points following administration of the investigational product/vaccine.	12-lead electrocardiogram（Heart Rate，bpm）	0-105 Days
Changes in 12-lead electrocardiogram findings from baseline at different observation time points following administration of the investigational product/vaccine.	12-lead electrocardiogram（ Heart Rhythm）	0-105 Days
Changes in 12-lead electrocardiogram findings from baseline at different observation time points following administration of the investigational product/vaccine.	12-lead electrocardiogram（ST Segment，mV）	0-105 Days
Changes in 12-lead electrocardiogram findings from baseline at different observation time points following administration of the investigational product/vaccine.	12-lead electrocardiogram（Abnormal Q Wave，ms）	0-105 Days
Changes in chest X-ray findings from baseline at different observation time points following administration of the investigational product/vaccine.	Chest X-ray（Cardiothoracic Ratio，>0.5）	0-105 Days
Changes in chest X-ray findings from baseline at different observation time points following administration of the investigational product/vaccine.	Chest X-ray（Pulmonary Nodule Size，mm）	0-105 Days
Changes in chest X-ray findings from baseline at different observation time points following administration of the investigational product/vaccine.	Chest X-ray（Costophrenic Angle，cm）	0-105 Days
Changes in chest X-ray findings from baseline at different observation time points following administration of the investigational product/vaccine.	Chest X-ray（Tracheal Position，cm）	0-105 Days
Changes in complete blood count (CBC) results from baseline at different observation time points following administration of the investigational product/vaccine.	White Blood Cell Count（×10⁹/L）	0-105 Days
Changes in complete blood count (CBC) results from baseline at different observation time points following administration of the investigational product/vaccine.	Hemoglobin（g/L）	0-105 Days
Changes in complete blood count (CBC) results from baseline at different observation time points following administration of the investigational product/vaccine.	Platelet Count（×10⁹/L）	0-105 Days
Changes in complete blood count (CBC) results from baseline at different observation time points following administration of the investigational product/vaccine.	Neutrophil Percentage（%）	0-105 Days
Changes in urinalysis results from baseline at different observation time points following administration of the investigational product/vaccine.	Protein（g/L）	0-105 Days
Changes in urinalysis results from baseline at different observation time points following administration of the investigational product/vaccine.	Glucose（mmol/L）	0-105 Days
Changes in urinalysis results from baseline at different observation time points following administration of the investigational product/vaccine.	White Blood Cells in Urine（/μL）	0-105 Days
Changes in urinalysis results from baseline at different observation time points following administration of the investigational product/vaccine.	Urine Erythrocytes （/μL）	0-105 Days
Changes in blood biochemistry results from baseline at different observation time points following administration of the investigational product/vaccine.	Blood Glucose （mmol/L）	0-105 Days
Changes in blood biochemistry results from baseline at different observation time points following administration of the investigational product/vaccine.	Potassium （mmol/L）	0-105 Days
Changes in blood biochemistry results from baseline at different observation time points following administration of the investigational product/vaccine.	Creatinine （µmol/L）	0-105 Days
Changes in blood biochemistry results from baseline at different observation time points following administration of the investigational product/vaccine.	Alanine Aminotransferase（U/L）	0-105 Days
Changes in blood biochemistry results from baseline at different observation time points following administration of the investigational product/vaccine.	Sodium（mmol/L）	0-105 Days
Changes in blood biochemistry results from baseline at different observation time points following administration of the investigational product/vaccine.	estimated Glomerular Filtration Rate（mL/min/1.73m²）	0-105 Days
Changes in routine coagulation test results from baseline at different observation time points following administration of the investigational product/vaccine.	Prothrombin Time（s）	0-105 days
Pharmacodynamic Endpoints	The positive rate (with a positivity threshold of RVNA ≥ 0.5 IU/mL) of serum rabies virus neutralizing antibodies (RVNA) were measured at the following time points: within 1 hour before the administration of the investigational product on Day 0, and at 4 hours, 6 hours, 12 hours, 1 day, 2 days, 3 days, 5 days, 7 days, 10 days, 14 days, 28 days, 42 days, 56 days, 84 days, and 105 days after the administration of the investigational product/vaccine.	0-105 Days
Pharmacodynamic Endpoints	The geometric mean concentration (GMC) of serum rabies virus neutralizing antibodies (RVNA) were measured at the following time points: within 1 hour before the administration of the investigational product on Day 0, and at 4 hours, 6 hours, 12 hours, 1 day, 2 days, 3 days, 5 days, 7 days, 10 days, 14 days, 28 days, 42 days, 56 days, 84 days, and 105 days after the administration of the investigational product/vaccine.	0-105 Days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetic Endpoints	The concentrations of LZR08 and LZR07 antibodies in serum were measured within 1 hour before the administration of the investigational product on Day 0 and at 12 hours, 1 day, 2 days, 3 days, 5 days, 7 days, 10 days, 14 days, 28 days, 42 days, 56 days, 84 days, and 105 days after the administration of the investigational product/vaccine. The following pharmacokinetic (PK) endpoints were calculated: Cmax.	105 Days
Pharmacokinetic Endpoints	The concentrations of LZR08 and LZR07 antibodies in serum were measured within 1 hour before the administration of the investigational product on Day 0 and at 12 hours, 1 day, 2 days, 3 days, 5 days, 7 days, 10 days, 14 days, 28 days, 42 days, 56 days, 84 days, and 105 days after the administration of the investigational product/vaccine. The following pharmacokinetic (PK) endpoints were calculated: AUC0-t.	105 Days
Pharmacokinetic Endpoints	The concentrations of LZR08 and LZR07 antibodies in serum were measured within 1 hour before the administration of the investigational product on Day 0 and at 12 hours, 1 day, 2 days, 3 days, 5 days, 7 days, 10 days, 14 days, 28 days, 42 days, 56 days, 84 days, and 105 days after the administration of the investigational product/vaccine. The following pharmacokinetic (PK) endpoints were calculated: AUC0-∞.	105 Days
Pharmacokinetic Endpoints	The concentrations of LZR08 and LZR07 antibodies in serum were measured within 1 hour before the administration of the investigational product on Day 0 and at 12 hours, 1 day, 2 days, 3 days, 5 days, 7 days, 10 days, 14 days, 28 days, 42 days, 56 days, 84 days, and 105 days after the administration of the investigational product/vaccine. The following pharmacokinetic (PK) endpoints were calculated: Tmax.	105 Days
Pharmacokinetic Endpoints	The concentrations of LZR08 and LZR07 antibodies in serum were measured within 1 hour before the administration of the investigational product on Day 0 and at 12 hours, 1 day, 2 days, 3 days, 5 days, 7 days, 10 days, 14 days, 28 days, 42 days, 56 days, 84 days, and 105 days after the administration of the investigational product/vaccine. The following pharmacokinetic (PK) endpoints were calculated: t1/2.	105 Days
Pharmacokinetic Endpoints	The concentrations of LZR08 and LZR07 antibodies in serum were measured within 1 hour before the administration of the investigational product on Day 0 and at 12 hours, 1 day, 2 days, 3 days, 5 days, 7 days, 10 days, 14 days, 28 days, 42 days, 56 days, 84 days, and 105 days after the administration of the investigational product/vaccine. The following pharmacokinetic (PK) endpoints were calculated: Vd/F.	105 Days
Pharmacokinetic Endpoints	The concentrations of LZR08 and LZR07 antibodies in serum were measured within 1 hour before the administration of the investigational product on Day 0 and at 12 hours, 1 day, 2 days, 3 days, 5 days, 7 days, 10 days, 14 days, 28 days, 42 days, 56 days, 84 days, and 105 days after the administration of the investigational product/vaccine. The following pharmacokinetic (PK) endpoints were calculated: Kel.	105 Days
Pharmacokinetic Endpoints	The concentrations of LZR08 and LZR07 antibodies in serum were measured within 1 hour before the administration of the investigational product on Day 0 and at 12 hours, 1 day, 2 days, 3 days, 5 days, 7 days, 10 days, 14 days, 28 days, 42 days, 56 days, 84 days, and 105 days after the administration of the investigational product/vaccine. The following pharmacokinetic (PK) endpoints were calculated: MRT.	105 Days
Pharmacokinetic Endpoints	The concentrations of LZR08 and LZR07 antibodies in serum were measured within 1 hour before the administration of the investigational product on Day 0 and at 12 hours, 1 day, 2 days, 3 days, 5 days, 7 days, 10 days, 14 days, 28 days, 42 days, 56 days, 84 days, and 105 days after the administration of the investigational product/vaccine. The following pharmacokinetic (PK) endpoints were calculated: CL/F.	105 Days
Anti-drug Antibodies (ADA)	The positive rate of serum anti-drug antibodies (ADA) against LZR08/LZR07 were assessed within 1 hour before the administration of the investigational product on Day 0 and at 7 days, 28 days, 56 days, 84 days, and 105 days after the administration of the investigational product/vaccine. For trial participants who tested positive for ADA, further evaluation was conducted to determine whether these were neutralizing antibodies against LZR08/LZR07.	105 Days
Anti-drug Antibodies (ADA)	The titer of serum anti-drug antibodies (ADA) against LZR08/LZR07 were assessed within 1 hour before the administration of the investigational product on Day 0 and at 7 days, 28 days, 56 days, 84 days, and 105 days after the administration of the investigational product/vaccine. For trial participants who tested positive for ADA, further evaluation was conducted to determine whether these were neutralizing antibodies against LZR08/LZR07.	105 Days

Collaborators and Investigators

• Sponsor: Lanzhou Institute of Biological Products Co., Ltd
• Investigators: Principal Investigator: Chaolin Huang, Wuhan Jinyintan Hospital

Study record dates

Study Major Dates

• Study Start (Estimated): January 31, 2026
• Primary Completion (Estimated): July 29, 2026
• Study Completion (Estimated): August 21, 2026

Study Registration Dates

• First Submitted: January 26, 2026
• First Submitted That Met QC Criteria: February 25, 2026
• First Posted (Actual): March 3, 2026

Study Record Updates

• Last Update Posted (Actual): March 3, 2026
• Last Update Submitted That Met QC Criteria: February 25, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: Monoclonal Antibody; Rabies; Recombinant Human
• Additional Relevant MeSH Terms: Infections; RNA Virus Infections; Virus Diseases; Mononegavirales Infections; Rhabdoviridae Infections; Rabies; Biological Products; Complex Mixtures; Vaccines; Viral Vaccines; Rabies Vaccines
• Other Study ID Numbers: CNBG-CT-0282

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No